Patients with HIV and those with a history of intravenous drug use may have significantly higher rates of hepatic steatosis, according to research results presented at the virtual Conference on Retroviruses and Opportunistic Infections, held from March 8 to 11, 2020. Two groups of researchers examined the role of hepatic steatosis across these patient populations.…
Hepatitis B virus prevalence was 7 to 10 times higher in a homeless population of Los Angeles compared to the general population of the United States.
A study identifies risk factors for hepatocellular carcinoma (HCC) after the first 5 years of receiving antiviral therapy in white patients with chronic hepatitis B.
The USPSTF recommends screening for hepatitis C virus infection in all adults.
Primary vaccination against hepatitis B virus (HBV) at birth may not provide adequate lifelong antibody levels, but a booster vaccine at age 18 years reinforces antibody levels for at least 4 more years.
An elevated fatty liver index appears to be a risk factor for all-cause mortality in patients coinfected with HIV and hepatitis C virus.
The study researchers concluded that different DAA therapies may be safely used with high SVR12 rates in patients with HCV and GFR less than 30 ml/min, except for ribavirin due to poor tolerability.
Patients who received heart transplants from hepatitis C virus-positive vs -negative donors were found to have comparable survival at 1 year and patients who developed transplant-related hepatitis C responded well to treatment.
Adult heart transplants from hepatitis C virus-positive donors appear safe, with no increased risk for adverse effects on one-year survival.
Viral hepatitis causing concomitant acute pancreatitis is a rare entity and outcomes vary depending on the type of hepatitis virus.
